Global Prescription Drugs Market to Reach $3 Trillion by 2030

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

 | Source: ReportLinker ReportLinker

New York, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Prescription Drugs Industry" - https://www.reportlinker.com/p06345721/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Prescription Drugs Market to Reach $3 Trillion by 2030

In the changed post COVID-19 business landscape, the global market for Prescription Drugs estimated at US$1.9 Trillion in the year 2022, is projected to reach a revised size of US$3 Trillion by 2030, growing at a CAGR of 5.9% over the analysis period 2022-2030. Generics, one of the segments analyzed in the report, is projected to record a 5.8% CAGR and reach US$498 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Orphan Drugs segment is readjusted to a revised 6.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $523.4 Billion, While China is Forecast to Grow at 9.5% CAGR

The Prescription Drugs market in the U.S. is estimated at US$523.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$668.3 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 6.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$416.2 Billion by the year 2030.

Select Competitors (Total 23 Featured)
- AbbVie, Inc.
- Allergan PLC
- Amgen, Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Novo Nordisk A/S
- Pfizer, Inc.
- Sanofi
- Shire PLC
- Teva Pharmaceutical Industries Ltd.


Read the full report: https://www.reportlinker.com/p06345721/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Prescription Drugs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Prescription Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Prescription Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Prescription Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Generics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Generics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 6: World 16-Year Perspective for Generics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Orphan Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Orphan Drugs by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 9: World 16-Year Perspective for Orphan Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for
Other Types by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Other Types by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 12: World 16-Year Perspective for Other Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR

Table 15: World 16-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Anti-Diabetics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Anti-Diabetics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Anti-Diabetics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Sensory Organs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Sensory Organs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Sensory Organs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Immunosuppressants by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Immunosuppressants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Immunosuppressants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Anticoagulants by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Anticoagulants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Anticoagulants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for
Other Therapies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Other Therapies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 30: World 16-Year Perspective for Other Therapies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 31: World Prescription Drugs Market Analysis of Annual
Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 32: USA Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 33: USA Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 34: USA 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 35: USA Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 36: USA Historic Review for Prescription Drugs by Therapy -
Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 37: USA 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

CANADA
Table 38: Canada Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 39: Canada Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 40: Canada 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 41: Canada Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 42: Canada Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 43: Canada 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

JAPAN
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 44: Japan Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 45: Japan Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 46: Japan 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 47: Japan Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 48: Japan Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 49: Japan 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

CHINA
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 50: China Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 51: China Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 52: China 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 53: China Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 54: China Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 55: China 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

EUROPE
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 56: Europe Recent Past, Current & Future Analysis for
Prescription Drugs by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 57: Europe Historic Review for Prescription Drugs by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 58: Europe 16-Year Perspective for Prescription Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030

Table 59: Europe Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 60: Europe Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 61: Europe 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 62: Europe Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 63: Europe Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 64: Europe 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

FRANCE
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 65: France Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 66: France Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 67: France 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 68: France Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 69: France Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 70: France 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

GERMANY
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 71: Germany Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 72: Germany Historic Review for Prescription Drugs by
Type - Generics, Orphan Drugs and Other Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 73: Germany 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 74: Germany Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 75: Germany Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 76: Germany 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

ITALY
Table 77: Italy Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 78: Italy Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 79: Italy 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 80: Italy Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 81: Italy Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 82: Italy 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

UNITED KINGDOM
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 83: UK Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 84: UK Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 85: UK 16-Year Perspective for Prescription Drugs by Type -
Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 86: UK Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 87: UK Historic Review for Prescription Drugs by Therapy -
Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 88: UK 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

SPAIN
Table 89: Spain Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 90: Spain Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 91: Spain 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 92: Spain Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 93: Spain Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 94: Spain 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

RUSSIA
Table 95: Russia Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 96: Russia Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 97: Russia 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 98: Russia Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 99: Russia Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 100: Russia 16-Year Perspective for Prescription Drugs by
Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

REST OF EUROPE
Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Prescription Drugs by Type - Generics, Orphan
Drugs and Other Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2022 through 2030 and % CAGR

Table 102: Rest of Europe Historic Review for Prescription
Drugs by Type - Generics, Orphan Drugs and Other Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 103: Rest of Europe 16-Year Perspective for Prescription
Drugs by Type - Percentage Breakdown of Value Sales for
Generics, Orphan Drugs and Other Types for the Years 2014, 2023 &
2030

Table 104: Rest of Europe Recent Past, Current & Future
Analysis for Prescription Drugs by Therapy - Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 105: Rest of Europe Historic Review for Prescription
Drugs by Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 106: Rest of Europe 16-Year Perspective for Prescription
Drugs by Therapy - Percentage Breakdown of Value Sales for
Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

ASIA-PACIFIC
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Prescription Drugs by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 108: Asia-Pacific Historic Review for Prescription Drugs
by Geographic Region - Australia, India, South Korea and Rest
of Asia-Pacific Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2014 through 2021 and % CAGR

Table 109: Asia-Pacific 16-Year Perspective for Prescription
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2014, 2023 & 2030

Table 110: Asia-Pacific Recent Past, Current & Future Analysis
for Prescription Drugs by Type - Generics, Orphan Drugs and
Other Types - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR

Table 111: Asia-Pacific Historic Review for Prescription Drugs
by Type - Generics, Orphan Drugs and Other Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 112: Asia-Pacific 16-Year Perspective for Prescription
Drugs by Type - Percentage Breakdown of Value Sales for
Generics, Orphan Drugs and Other Types for the Years 2014, 2023 &
2030

Table 113: Asia-Pacific Recent Past, Current & Future Analysis
for Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 114: Asia-Pacific Historic Review for Prescription Drugs
by Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 115: Asia-Pacific 16-Year Perspective for Prescription
Drugs by Therapy - Percentage Breakdown of Value Sales for
Oncology, Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

AUSTRALIA
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Australia for 2023 (E)
Table 116: Australia Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 117: Australia Historic Review for Prescription Drugs by
Type - Generics, Orphan Drugs and Other Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 118: Australia 16-Year Perspective for Prescription Drugs
by Type - Percentage Breakdown of Value Sales for Generics,
Orphan Drugs and Other Types for the Years 2014, 2023 & 2030

Table 119: Australia Recent Past, Current & Future Analysis for
Prescription Drugs by Therapy - Oncology, Anti-Diabetics,
Sensory Organs, Immunosuppressants, Anticoagulants and Other
Therapies - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR

Table 120: Australia Historic Review for Prescription Drugs by
Therapy - Oncology, Anti-Diabetics, Sensory Organs,
Immunosuppressants, Anticoagulants and Other Therapies Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR

Table 121: Australia 16-Year Perspective for Prescription Drugs
by Therapy - Percentage Breakdown of Value Sales for Oncology,
Anti-Diabetics, Sensory Organs, Immunosuppressants,
Anticoagulants and Other Therapies for the Years 2014, 2023 &
2030

INDIA
Prescription Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in India for 2023 (E)
Table 122: India Recent Past, Current & Future Analysis for
Prescription Drugs by Type - Generics, Orphan Drugs and Other
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2022 through 2030 and % CAGR

Table 123: India Historic Review for Prescription Drugs by Type -
Generics, Orphan Drugs and Other Types Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR

Table 124: India 16-Year Perspective for Prescription Drugs by
Type - Percentage Breakdown of Value Sales for Generics, Orphan
Drugs and Other Types for the Years 2014, 2023 & 2030

Table 125: India Recent Past, Current & Future Analysis for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06345721/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

 

            











    

        

        
Contact Data

        


    
    

 
    



        

        
            GlobeNewswire